Invasive ductal breast carcinoma is the most widespread form of breast cancer, accounting for approximately 80% of all cases. While the diagnosis brings understandable concern, understanding treatment pathways—both established and experimental—can help patients and families navigate decisions with greater confidence and clarity.

Understanding Treatment Goals and Available Paths

The treatment of invasive ductal carcinoma aims to remove or destroy cancer cells, prevent the disease from spreading to other parts of the body, and reduce the chance of the cancer returning after initial treatment. Depending on the stage at which the cancer is discovered, therapy may focus on curing the disease entirely or managing symptoms and slowing its progression when cancer has spread beyond the breast.^[1]

Each person’s treatment plan is uniquely tailored. Healthcare teams consider multiple factors when deciding which therapies to recommend, including the size and location of the tumor, whether cancer cells have reached the lymph nodes under the arm, how quickly the cancer cells are growing, and whether the tumor responds to hormones like estrogen or progesterone or to a protein called HER2. Age, general health, menopausal status, and personal preferences also play an important role in shaping treatment decisions.^[5]

Medical societies and cancer organizations have established guidelines for treating invasive ductal carcinoma based on decades of research. These standard treatments have been tested extensively and are known to be effective for most patients. At the same time, scientists continue to investigate new drugs and methods through clinical trials—carefully designed research studies that test whether experimental treatments are safe and work better than existing options.^[18]

Standard Treatment Options

Surgery is nearly always a central part of treating invasive ductal carcinoma. The goal is to remove the cancerous tissue from the breast and determine whether the disease has reached nearby lymph nodes. There are two main types of breast surgery: lumpectomy, which removes the tumor and a small margin of healthy tissue around it while preserving most of the breast, and mastectomy, which removes the entire breast. The choice between these procedures depends on the tumor’s size and location, the size of the breast, patient preference, and whether cancer appears in multiple areas of the breast.^[10]

Surgeons often check the lymph nodes in the underarm area during surgery to see if cancer has spread beyond the breast. Depending on what they find, they may remove a few lymph nodes or a larger number. If the entire breast is removed, some women may choose breast reconstruction, a procedure that rebuilds the breast shape either at the same time as the mastectomy or during a later operation.^[6]

Following surgery, most patients receive additional treatments designed to destroy any remaining cancer cells that might not be visible on scans or during the operation. Radiation therapy uses high-energy beams to target and kill cancer cells in the breast area and nearby lymph nodes. It is commonly recommended after lumpectomy to reduce the chance of cancer returning in the same breast. The treatment is delivered externally, with the patient lying under a machine that directs radiation to the specific area, or occasionally through a small implant placed temporarily inside the breast.^[10]

Chemotherapy involves using powerful drugs to destroy cancer cells throughout the body. These medications may be given as pills or through an intravenous line. Chemotherapy is often used before surgery—called neoadjuvant therapy—to shrink large tumors and make them easier to remove. It can also be given after surgery to eliminate any cancer cells that may have traveled to other parts of the body. The specific drugs and duration of chemotherapy depend on the cancer’s characteristics and stage.^[6]

The side effects of chemotherapy vary from person to person but may include fatigue, nausea, hair loss, increased risk of infection, and changes in appetite. Some of these effects are temporary and resolve after treatment ends, while others may persist longer. Healthcare teams work closely with patients to manage these side effects and maintain quality of life during treatment.^[4]

Many invasive ductal carcinomas are hormone receptor-positive, meaning the cancer cells have receptors on their surface that allow hormones like estrogen and progesterone to fuel their growth. For these cancers, hormone therapy (also called endocrine therapy) is a highly effective treatment. These drugs work by blocking the body’s natural hormones from reaching cancer cells or by lowering the amount of hormones the body produces. Common hormone therapy drugs include tamoxifen, which blocks estrogen receptors, and aromatase inhibitors like letrozole, anastrozole, and exemestane, which reduce estrogen production in postmenopausal women.^[5]

Hormone therapy is usually taken for several years—often five to ten years—to reduce the risk of cancer returning. Side effects can include hot flashes, joint pain, vaginal dryness, mood changes, and an increased risk of bone thinning. Regular monitoring and supportive care help manage these effects over the long term.^[18]

Targeted therapy refers to drugs that attack specific features of cancer cells. One of the most well-known targeted therapies is used for cancers that are HER2-positive, meaning the cancer cells produce too much of a protein called HER2, which promotes rapid cell growth. Drugs like trastuzumab (Herceptin), pertuzumab, and ado-trastuzumab emtansine work by blocking HER2 and slowing or stopping the growth of these cancer cells. These medications are often given along with chemotherapy and have significantly improved outcomes for patients with HER2-positive breast cancer.^[5]

Treatment plans are not one-size-fits-all. A medical team that includes surgeons, oncologists (cancer doctors), radiation specialists, and nurses collaborates to design the best approach for each individual. They also provide support for emotional and physical well-being throughout the journey.^[4]

Treatment in Clinical Trials

While standard treatments have proven effective for many patients, researchers are constantly working to develop better therapies that might work faster, cause fewer side effects, or help patients whose cancer does not respond to existing drugs. This work happens through clinical trials—research studies that test new treatments before they become widely available. Participating in a clinical trial gives patients access to cutting-edge therapies while contributing to scientific knowledge that may benefit future patients.^[4]

Clinical trials are carefully designed and follow strict safety rules. They are divided into phases. Phase I trials focus on testing whether a new drug or treatment is safe and determining the right dose. These studies involve a small number of participants and closely monitor for side effects. Phase II trials expand the group of participants and begin to evaluate whether the treatment actually works against the cancer. Phase III trials compare the new treatment to the current standard treatment to see if the new approach offers better results, such as longer survival or fewer side effects.^[5]

Clinical trials for invasive ductal carcinoma are taking place in many countries, including the United States, Canada, and across Europe. Patients may be eligible depending on factors like the stage and type of their cancer, previous treatments, and overall health. Doctors and research coordinators help determine whether a specific trial is a good fit.^[18]

Several innovative therapies are currently being studied in clinical trials for invasive ductal carcinoma. One promising area is immunotherapy, which uses the body’s own immune system to fight cancer. The immune system normally protects the body from infections and diseases, but cancer cells can sometimes hide from it. Immunotherapy drugs help the immune system recognize and attack cancer cells more effectively. These treatments are being tested especially for aggressive forms of breast cancer, such as triple-negative breast cancer, which does not respond to hormone therapy or HER2-targeted drugs.^[5]

Another area of active research involves drugs that target specific molecular pathways inside cancer cells. For example, scientists are studying CDK4/6 inhibitors, which block proteins that help cancer cells divide and grow. These drugs are often combined with hormone therapy and have shown promise in slowing cancer progression in patients with hormone receptor-positive disease. Examples include palbociclib, ribociclib, and abemaciclib.^[18]

Researchers are also exploring drugs called PARP inhibitors, which interfere with a cancer cell’s ability to repair its DNA. These drugs are particularly useful for patients who have inherited mutations in genes like BRCA1 or BRCA2, which increase breast cancer risk. By blocking the repair process, PARP inhibitors cause cancer cells to die. Clinical trials are testing whether these drugs can help more patients beyond those with BRCA mutations.^[18]

Some clinical trials focus on improving existing treatments by combining them in new ways or adjusting when and how they are given. For instance, researchers are testing whether giving certain chemotherapy drugs before surgery leads to better outcomes than giving them afterward. Others are studying whether shorter or less intense radiation schedules can be just as effective as longer courses while reducing side effects.^[6]

Early results from some clinical trials have been encouraging. For example, studies of immunotherapy combined with chemotherapy have shown improved response rates in certain patients with triple-negative breast cancer, leading to new treatment approvals. Similarly, trials of targeted drugs for HER2-low breast cancer—a subtype that has small amounts of HER2 but not enough to qualify as HER2-positive—have opened new treatment possibilities for a group of patients who previously had limited options.^[18]

Patients interested in clinical trials should discuss the option with their healthcare team. Doctors can help identify appropriate studies and explain how participation might fit into the overall treatment plan. Many cancer centers maintain lists of active trials and can assist with enrollment.^[4]

Most common treatment methods

• Surgery
  • Lumpectomy removes the tumor and a margin of healthy tissue while preserving most of the breast
  • Mastectomy removes the entire breast
  • Lymph node removal checks whether cancer has spread beyond the breast
  • Breast reconstruction rebuilds breast shape after mastectomy
• Radiation therapy
  • Uses high-energy beams to destroy cancer cells in the breast and nearby areas
  • Commonly given after lumpectomy to reduce recurrence risk
  • Can be delivered externally or through temporary implants
• Chemotherapy
  • Uses drugs to destroy cancer cells throughout the body
  • May be given before surgery to shrink tumors (neoadjuvant therapy) or after surgery
  • Side effects include fatigue, nausea, hair loss, and increased infection risk
• Hormone therapy
  • Blocks hormones like estrogen from fueling cancer growth in hormone receptor-positive cancers
  • Common drugs include tamoxifen and aromatase inhibitors (letrozole, anastrozole, exemestane)
  • Usually taken for five to ten years after initial treatment
• Targeted therapy
  • Attacks specific features of cancer cells, such as HER2 protein
  • Drugs like trastuzumab and pertuzumab block HER2 in HER2-positive cancers
  • CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) slow cancer cell division
  • PARP inhibitors interfere with cancer cell DNA repair, especially in BRCA mutation carriers
• Immunotherapy
  • Helps the immune system recognize and attack cancer cells
  • Being tested in clinical trials, especially for triple-negative breast cancer
  • May be combined with chemotherapy to improve response rates